THC-O-acetate and the Continued Pharma Patents: New Update

There's been continued activity in the creation of pharma drugs with cannabinoids – and many of them are created in the lab. One that the GCRC follows is that of THC-O-acetate in pain management via transdermal delivery systems by a very well known researcher and her team, Audra Stinchcomb of Zynerba pharmaceuticals. They've been at it again this month with an update only days ago on their patent. It's intriguing to delved into their work as I personally embark on a mission to use this cannabinoid constituent while attempting to regain footing with the Department of Motor Vehicles – for the next 18 months I'll be under watch so to say.

If I make it without seizure the permanent medical suspension put on my drivers license after being paralyzed in an auto racing wreck will be lifted and the Epilepsy 'ban on driving' will be changed to limitations. It's a long journey to gain this as it's nearly unheard of but THC-O was the cannabinoid of choice for me – and it's very hard to get.

Among other things the patent applications and updates go over several key facts including that Pain is the most frequently reported symptom and it is a common clinical problem which confronts all clinicians. This entity has been working on a delivery system that surrounds a Pro Drug use of the Cannabinoid or a continued delivery via transdermal. Hundreds of millions of people suffer from severe pain and according to numerous recent reports, is chronically under-treated or inappropriately managed.

As well, a “wasting syndrome” which generally describes a clinical syndrome in which a person has lost more than 10% of his or her body weight in the absence other obvious reasons such as infectious disease, is also the target of the patents. Treatment of malabsorption, diarrhea, reduced food intake or altered metabolism are on the list to name a few.

The recent patent activity targets the use of THC-O-acetate to treat the co-morbid conditions that are secondary to chemotherapy and human immunodeficiency virus infection (a.k.a HIV-wasting). It specifically states "Cannabinoids, such as Δ9-THC, are effective in treating and alleviating wasting syndromes, including, but not limited to HIV-wasting and chemotherapy induced wasting. Indeed, Δ9-THC is currently available in an oral dosage, sold under the trade name Marinol®, to treat this indication."

What we find is that all too frequently that many of the patients suffering from chronic, under-treated or unretractable pain, also suffer from lack of appetite, nausea and/or frequent emesis, so bad that they can't even take their pharmaceuticals they use. Basically their medications are making them sick and this high powered cannabinoid can change that – with my own experience I can firmly state they are 100% correct from findings based on just one person – the founder of the GCRC.

The clinical usefulness of the cannabinoids, including Δ9-tetrahydrocannabinol (Δ9-THC), to provide analgesia, help alleviate nausea and emesis, as well as stimulate appetite has been well-recognized.

Nextleaf Solutions Ltd gained a patent last year on the same compound using a different technology. The Canadian Intellectual Property Office granted the company a patent covering the creation of a THC prodrug, its 40th issued patent.

Specifically, the patent describes a process for acetylating (inserting an acetyl group into a compound) delta 9-tetrahydrocannabinol (THC) and refining it into THC-O-Acetate using salting-out assisted liquid-liquid extraction and distillation techniques. "Nextleaf's patented process to produce THC-O-Acetate enables the standardization of a more potent analog of THC, an alternative option to experience the unique medicinal benefits, associated with targeted drug delivery," CEO Paul Pedersen said in a statement. "The potency of THC-O-Acetate is said to be 300% that of THC with potentially psychedelic features."

Without a doubt there's plenty of movement in the pharmaceutical end of Cannabinoid medicine and these two entities are, by far, not the only ones gaining patents on technologies and inventions. It's important to note that the cannabinoid itself can not be patented – it's how it's made – and in this case we're talking a lab creation vs. what the plant makes on it's own. And as a well spoken patient, this is where I chime in loudly and state that hey – without these lab creations I wouldn't be looking at the possibility of driving again.

I needed a more potent version of THC and this is about the only way to get it – I don't have much but what I do is like a treasure and only a little is needed. When balancing the Endocannabinoid system with minor constituents and other forms of THC both ingested and inhaled in vapors I find the ultimate efficacy – one that might allow me to make it the year plus process of hearings and more involved in regaining a limited license to drive with medical conditions.

With one pharmaceutical still on board for Epilepsy the choice was made for THC-O-acetate with the input of a UCLA Neurologist who's been engaged for help in the cessation of the final drug from the old world of Big Pharma. The bold message I'm sending to my friends who love the plant is that I need this version right now – 2020 wasn't kind and a repeat of it will ensure I never get behind a wheel again.

At this point we're just hoping to lift the permanent suspension as that's phase one in gaining a release. One would think there was a crime committed and THC-O-acetate is the awesome defense attorney that will gain freedom for the 'guilty party'. Sadly, when looking for reinstatement of a license to operate a vehicle with Epilepsy, one faces much controversy.

I'll be looking to this multi patented cannabinoid concoction in various ways to attempt to gain that freedom back that so many, including myself decades ago, take for granted on a daily basis.

Plant medicine and driving – two things that most of us never quite think will go hand in hand especially with a stronger version of THC. But, in this case it's the 'Hope'.

Thank you for visiting the GCRC Website,

–Mike Robinson, Founder – Global Cannabinoid Research Center

Contact Mike today about opportunities with GCRC 

References:

PATENT: PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME

Nextleaf Press Release: TCH-O-acetate Patent